REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Phase of Trial: Phase I/II
Latest Information Update: 12 Mar 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms REACTION
- 07 Mar 2019 Status changed from not yet recruiting to recruiting.
- 02 Jan 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
- 20 Dec 2018 Planned End Date changed from 1 Feb 2024 to 1 Apr 2024.